首页>
外文期刊>Prescrire international
>Prolonged-release aripiprazole for injection: a double dose now authorised at the start of treatment, but with no clinical evaluation
【24h】
Prolonged-release aripiprazole for injection: a double dose now authorised at the start of treatment, but with no clinical evaluation
展开▼
机译：Prolonged-release aripiprazole for injection: a double dose now authorised at the start of treatment, but with no clinical evaluation
Aripiprazole is a so-called atypical neuroleptic. In the form of powder and solvent for injection of a prolonged-release suspension (Ability Maintena°), it is authorised in the European Union for "maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole". Its evaluation at a dose of 400 mg by intramuscular injection every month did not demonstrate any additional benefit compared to the oral route, but it was associated with an increase in extrapyramidal adverse effects. These adverse effects add to the other adverse effects of neuroleptics, which include sedative and antimuscarinic actions, cardiac effects (arrhythmia, myocardial infarction), plus suicidal thoughts and behaviour and impulse control disorders (1-3).
展开▼
